Human type 3 5α-reductase is expressed in peripheral tissues at higher levels than types 1 and 2 and its activity is potently inhibited by finasteride and dutasteride

Hormone Molecular Biology and Clinical Investigation

Volumn 2, Issue 3, 2010, Pages 293-299

  Yamana, Kazutoshi ^a   Fernand, Labrie ^a   Luu The, Van ^a  

^a UNIVERSITÉ LAVAL   (Canada)

Author keywords

androgen; dihydrotestosterone; dutasteride; finasteride; SRD5a 3; steroidogenesis; type 3 5 reductase

Indexed keywords

5 ALPHA REDUCTASE 1; 5 ALPHA REDUCTASE 2; 5 ALPHA REDUCTASE 3; ANDROSTANEDIONE; ANDROSTANOLONE; ANDROSTENEDIONE; DUTASTERIDE; FINASTERIDE; OXIDOREDUCTASE; TESTOSTERONE; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; AMINO TERMINAL SEQUENCE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER CELL LINE; DRUG POTENCY; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION; HEK293 CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; IC50; MALE; MAMMARY GLAND; PRIORITY JOURNAL; PROSTATE CANCER CELL LINE; PROSTATE TISSUE; REAL TIME POLYMERASE CHAIN REACTION; TISSUE DISTRIBUTION;

EID: 84919787382     PISSN: 18681883     EISSN: 18681891     Source Type: Journal    
DOI: 10.1515/HMBCI.2010.035     Document Type: Article

References (24)

1. Wilson JD. Sexual differentiation. Annu Rev Physiol 1978;40: 279-306.
2. Samson M., Labrie F., Luu-The V. Sequential transformation of 4-androstenedione into dihydrotestosterone in prostate carcinoma (DU-145) cells indicates that 4-androstenedione and not testosterone is the substrate of 5 alpha-reductase. Horm Mol Biol Clin Invest 2010;1:63-72.
3. Samson M., Labrie F., Zouboulis CC., Luu-The V. Biosynthesis of dihydrotestosterone by a pathway that does not require testosterone as an intermediate in the SZ95 sebaceous gland cell line. J Invest Dermatol 2010;130:602-4.
4. Andersson S., Russell DW. Structural and biochemical properties of cloned and expressed human and rat steroid 5 alpha-reductases. Proc Natl Acad Sci USA 1990;87:3640-4.
5. Andersson S., Berman DM., Jenkins EP., Russell DW. Deletion of steroid 5 alpha-reductase 2 gene in male pseudohermaphro-ditism. Nature 1991;354:159-61.
6. Jenkins EP., Hsieh CL., Milatovich A., Normington K., Berman DM., Francke U., Russell DW. Characterization and chromosomal mapping of a human steroid 5 alpha-reductase gene and pseudogene and mapping of the mouse homologue. Genomics 1991;11:1102-12.
7. Labrie F., Sugimoto Y., Luu-The V., Simard J., Lachance Y., Bach-varov D., Leblanc G., Durocher F., Paquet N. Structure of human type II 5 alpha-reductase gene. Endocrinology 1992;131:1571-3.
8. Sugimoto Y., Lopez-Solache I., Labrie F., Luu-The V. Cations inhibit specifically type I 5 alpha-reductase found in human skin. J Invest Dermatol 1995;104:775-8.
9. Luu-The V., Belanger A., Labrie F. Androgen biosynthetic pathways in the human prostate. Best Pract Res Clin Endocrinol Metab 2008;22:207-21.
10. Uemura M., Tamura K., Chung S., Honma S., Okuyama A., Naka-mura Y., Nakagawa H. Novel 5 alpha-steroid reductase (SRD5A3, type-3) is overexpressed in hormone-refractory prostate cancer. Cancer Sci 2008;99:81-6.
11. Luu-The V., Tremblay P., Labrie F. Characterization of type 12 17beta-hydroxysteroid dehydrogenase., an isoform of type 3 17beta-hydroxysteroid dehydrogenase responsible for estradiol formation in women. Mol Endocrinol 2006;20:437-443.
12. Dufort I., Rheault P., Huang X-F., Soucy P., Luu-The V. Characteristics of a highly labile human type 5 17beta-hydroxysteroid dehydrogenase. Endocrinology 1999;140:568-74.
13. Samson M., Labrie F., Luu-The V. Inhibition of human-type 1 3beta-hydroxysteroid deshydrogenase/Delta(5)-Delta(4)-isomer-ase expression using siRNA. J Steroid Biochem Mol Biol 2005;94:253-257.
14. Russell DW., Wilson JD. Steroid 5 alpha-reductase: two genes/ two enzymes. Annu Rev Biochem 1994;63:25-61.
15. Bramson HN., Hermann D., Batchelor KW., Lee FW., James MK., Frye SV. Unique preclinical characteristics of GG745, a potent dual inhibitor of 5AR. J Pharmacol Exp Ther 1997;282:1496-502.
16. Roehrborn CG., Boyle P., Nickel JC., Hoefner K., Andriole G. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002;60:434-41.
17. Baker ME. Steroid receptor phylogeny and vertebrate origins. Mol Cell Endocrinol 1997;135:101-7.
18. Bertrand S., Brunet FG., Escriva H., Parmentier G., Laudet V., Robinson-Rechavi M. Evolutionary genomics of nuclear receptors: from twenty-five ancestral genes to derived endocrine systems. Mol Biol Evol 2004;21:1923-37.
19. Laudet V. Evolution of the nuclear receptor superfamily: early diversification from an ancestral orphan receptor. J Mol Endo-crinol 1997;19:207-26.
20. Moon YA., Horton JD. Identification of two mammalian reductases involved in the two-carbon fatty acyl elongation cascade. J Biol Chem 2003;278:7335-43.
21. Entchev EV., Schwudke D., Zagoriy V., Matyash V., Bogdanova A., Habermann B., Zhu L., Shevchenko A., Kurzchalia TV. LET-767 is required for the production of branched chain and long chain fatty acids in Caenorhabditis elegans. J Biol Chem 2008;283:17550-60.
22. Desnoyers S., Blanchard P-G., St-Laurent J-F., Gagnon S., Baillie DL., Luu-The V. C. elegans LET-767 is able to metabolize andro-gens and estrogens and likely shares common ancestor with human types 3 and 12 17Β-hydroxysteroid dehydrogenases. J Endocrinol 2007;195:271-279.
23. Huang XF., Luu-The V. Gene structure., chromosomal localiza tion and analysis of 3-ketosteroid reductase activity of the human 3(alpha→beta)-hydroxysteroid epimerase. Biochim Biophys Acta 2001;1520:124-30.
24. Huang XF., Luu-The V. Molecular characterization of a first human 3(alpha→beta)-hydroxysteroid epimerase. J Biol Chem 2000;275:29452-7.